Have trouble viewing this email? View in web browser.
Patient-Hero
Patient-Hero
 
INTRODUCING THE HONESTLY TV COMMERCIAL
We're talking Honestly about HIV risk, prevention, and sexual health.
 
 
 
Dear Healthcare Provider,
 
Gilead Sciences, Inc. is excited to announce the launch of a new, national TV commercial with a big goal in mind: to raise awareness around HIV risk and all the ways your patients can help protect their sexual health.
 
The new commercial, titled "Honestly," aims to empower people to have honest conversations with their healthcare providers about sexual health and HIV prevention options.
 
Through the TV commercial, Gilead aims to reduce the stigma associated with HIV and empower patients to make informed decisions about their sexual health.
HONESTLY,
we’re excited to
show you!
Watch-The-TV-Commercial-Now
 
Your patients may come in having seen the TV commercial, ready to discuss HIV prevention. This is a great time to start an honest conversation about sexual health.
 
Your patients may ask about the following:
 
What HIV prevention options are available and which you'd recommend for them
 
Getting tested for HIV and STIs
 
How they can help protect their sexual health
 
Download a sexual health intake form >
 
Patient-Hero
Remember, some people may
not realize they're at risk for
HIV, so you can start the
honest conversation.
 
 
 
In the United States alone, 1.1 million individuals are estimated to be at elevated risk for sexually acquired HIV, with about 40,000 cases diagnosed annually.1,2
 
Check out the TV commercial and other sexual health resources for your patients at healthysexuals.com.
 
Sincerely,
Your HIV Prevention Team at Gilead
 
 
 
References: 1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2015; vol. 27. CDC website. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf. 2. Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291-1295.
Gilead-Logo
Gilead Corporate Website  |  Terms of Use  |  Privacy Policy  |  Contact Us  |  Unsubscribe
GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. or its related companies. All other marks referenced herein are the property of their respective owners.
©2018 Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404. All rights reserved.
UNBP3911 05/18